Cargando…

Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre

The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is potentially related to aggressive behavior and persistent disease. BRAF alterations other than the p.V600E are less common in thyroid carcinoma and represent an alternative mechanism of BRAF activati...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Leo, Antonio, Serban, Daniela, Maloberti, Thais, Sanza, Viviana, Coluccelli, Sara, Altimari, Annalisa, Gruppioni, Elisa, Chiarucci, Federico, Corradini, Angelo Gianluca, Repaci, Andrea, Colapinto, Alessandra, Nannini, Margherita, Pantaleo, Maria A., de Biase, Dario, Tallini, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958561/ https://www.ncbi.nlm.nih.gov/pubmed/36835466 http://dx.doi.org/10.3390/ijms24044057

Ejemplares similares

BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma
por: Repaci, Andrea, et al.
Publicado: (2019)

Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center
por: Maloberti, Thais, et al.
Publicado: (2022)

Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST
por: Nannini, Margherita, et al.
Publicado: (2020)

Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer
por: Maloberti, Thais, et al.
Publicado: (2023)

Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice
por: de Biase, Dario, et al.
Publicado: (2023)

Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel
por: de Biase, Dario, et al.
Publicado: (2020)

Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma
por: Ruscelli, Martina, et al.
Publicado: (2023)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Multifocal Fibrosing Thyroiditis: an Under-recognized Mimicker of Papillary Thyroid Carcinoma
por: Orsatti, Agnese, et al.
Publicado: (2022)

Relevance of ARID1A Mutations in Endometrial Carcinomas
por: De Leo, Antonio, et al.
Publicado: (2022)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

Molecular alterations in pancreatic tumors
por: Visani, Michela, et al.
Publicado: (2021)

454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples
por: Altimari, Annalisa, et al.
Publicado: (2013)

Diagnostic utility of BRAF(V600E )mutation testing in thyroid nodules in elderly patients
por: Guerra, Anna, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
por: Perrone, Fabiana, et al.
Publicado: (2022)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor
por: Pantaleo, Maria A., et al.
Publicado: (2022)

Detection of BRAF V600E in Fine-Needle Aspiration Samples of Thyroid Nodules by Droplet Digital PCR
por: Lu, Sang-Yu, et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Value of TIRADS, BSRTC and FNA-BRAF(V600E) mutation analysis in differentiating high-risk thyroid nodules
por: Zhang, Yu-zhi, et al.
Publicado: (2015)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel
por: Malvi, Deborah, et al.
Publicado: (2022)

RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAF(V600E) Mutation-Negative Nodules?
por: Yoon, Jung Hyun, et al.
Publicado: (2015)

Diagnostic value of BRAF(V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis
por: Su, Xingyun, et al.
Publicado: (2016)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

BRAF(V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules
por: Wu, Ya, et al.
Publicado: (2019)

Comparison of the Clinical Validity of Droplet Digital PCR to ARMS‐PCR for BRAF V600E Mutation Detection in Thyroid Nodules
por: Li, Xiubo, et al.
Publicado: (2020)

BRAF(V600E) mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
por: Chen, Huang, et al.
Publicado: (2021)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Is Follow-up BRAF(V600E) Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
por: Yoon, Jung Hyun, et al.
Publicado: (2013)

Increased diagnostic sensitivity of palpation‐guided thyroid nodule fine‐needle aspiration cytology by BRAF V600E‐mutation analysis
por: Gimm, Oliver, et al.
Publicado: (2021)

BRAF(V600E) genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration
por: Lu, Yiran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cinq20q1fc3q2lj8lo3snnaics